Publication:
Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma

Simple item page
dc.contributor.authorDANE, FAYSAL
dc.contributor.authorsBaykara, Meltem; Akkus, Murat; Yildiz, Ramazan; Gonul, Ipek Isik; Dursun, Ayse; Coskun, Ugur; Benekli, Mustafa; Sevinc, Alper; Dane, Faysal; Buyukberber, Suleyman
dc.date.accessioned2022-03-12T17:53:12Z
dc.date.available2022-03-12T17:53:12Z
dc.date.issued2011
dc.description.abstractThis study was designed to determine the level of survivin expression and its clinical significance as a prognostic factor in gastrointestinal stromal sarcoma (GIST). Twenty patients (12 males and 8 females) ranging in age from 25 to 72, with a median age of 53 were evaluated. Failure of TKI treatment was higher in the survivin-positive group (p= 0.06). The rate of metastasis was significantly higher in the survivin positive group vs. the negative group (80% vs. 30%, p =0.18). The median overall survival (OS) time was 114 (range 29-199) months, and the median disease-free survival (DFS) time was 88 (range 40-135) months. The median progression-free survival (PFS) time was 40 (range 24-55) months. Further, a comparison of patients with survivin positive versus negative tumors, revealed no significant difference for OS, DFS, and PFS (p = 0.45, p = 0.19, p= 0.55, respectively), number of mitoses in 50 HPF (p =0.14), and tumor size (p = 0.94). In conclusion, survivin was highly expressed in GISTs, although we found no correlation between survivin expression and PFS, DFS and OS, survivin may be a predictive marker in GISTs for disease progression. We believe that additional studies are warranted to determine the clinical significance of survivin expression as a prognostic or predictive marker in patients with GIST. Crown Copyright (C) 2011 Published by Elsevier B.V. All rights reserved.
dc.identifier.doi10.1016/j.intimp.2011.10.005
dc.identifier.eissn1878-1705
dc.identifier.issn1567-5769
dc.identifier.pubmed22020290
dc.identifier.urihttps://hdl.handle.net/11424/230451
dc.identifier.wosWOS:000298460700038
dc.language.isoeng
dc.publisherELSEVIER SCIENCE BV
dc.relation.ispartofINTERNATIONAL IMMUNOPHARMACOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectSurvivin
dc.subjectAnti-apoptosis
dc.subjectInhibitors of apoptosis proteins
dc.subjectGastrointestinal stromal sarcoma
dc.subjectANTI-APOPTOSIS GENE
dc.subjectDIFFERENTIAL-DIAGNOSIS
dc.subjectTHERAPEUTIC TARGET
dc.subjectCELL-PROLIFERATION
dc.subjectPROGNOSTIC-FACTORS
dc.subjectPANCREATIC-CANCER
dc.subjectGASTRIC-CANCER
dc.subjectGROWTH-FACTOR
dc.subjectTUMORS
dc.subjectINHIBITOR
dc.titleSurvivin expression and its potential clinical significance in gastrointestinal stromal sarcoma
dc.typearticle
dspace.entity.typePublication
local.avesis.ida835216d-a021-4029-8edb-da7d7404c33e
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.journal.numberofpages5
oaire.citation.endPage2231
oaire.citation.issue12
oaire.citation.startPage2227
oaire.citation.titleINTERNATIONAL IMMUNOPHARMACOLOGY
oaire.citation.volume11
relation.isAuthorOfPublication059ce50a-8d16-4fc6-a86c-85c9baa19a5c
relation.isAuthorOfPublication.latestForDiscovery059ce50a-8d16-4fc6-a86c-85c9baa19a5c

Files

Collections

Research Outputs